Workflow
医疗级热塑性聚氨酯(TPU)Desmopan® Rx系列产品
icon
Search documents
科思创,千亿收购遭调查!
DT新材料· 2025-07-29 16:05
Core Viewpoint - The acquisition of Covestro by ADNOC for €14.7 billion (approximately 121.7 billion yuan) is under investigation by the EU due to foreign subsidy concerns, with a final decision deadline set for December 2, 2025 [1][2]. Group 1: Acquisition Details - The acquisition deal began in October 2024, with ADNOC's commitment to future development leading to the signing of the agreement with Covestro [4]. - If successful, ADNOC will gain significant production capacities, including 1.59 million tons/year of PC, 1.77 million tons/year of MDI, and 830,000 tons/year of TDI [6]. - Covestro's portfolio includes low-carbon materials that align with ADNOC's clean energy strategies, enhancing its competitive position against major players like BASF and SABIC [7]. Group 2: Strategic Intentions - ADNOC aims to extend its petrochemical value chain into high-end materials, leveraging Covestro's customer networks in automotive and renewable energy sectors to mitigate traditional energy market volatility [5]. - ADNOC has allocated $150 billion for external investments, indicating a proactive approach to acquiring quality assets during challenging market conditions [9]. - The company is also planning to establish a world-class chemical complex in Al Dhafra, with an initial investment of $1.7 billion to build a green methanol plant [10]. Group 3: Covestro's Recent Developments - Covestro has been actively launching new products and forming partnerships, including a new series of post-consumer recycled polycarbonate and collaborations with major automotive companies [11]. - The company is expanding its production capabilities, with recent investments in facilities in the U.S. and Europe to meet growing demand in various sectors [13].
科思创,又一高端产品投产
DT新材料· 2025-07-06 15:39
Core Viewpoint - Covestro has officially launched its medical-grade thermoplastic polyurethane (TPU) Desmopan® Rx series at its Changhua site in Taiwan, marking it as the second facility globally to receive medical-grade TPU production certification, addressing the growing demand for high-performance medical materials in the Asia-Pacific market [1][2]. Group 1: Product and Production Details - The new production line adheres to Good Manufacturing Practice (GMP) standards, ensuring products are free from plasticizers and have low extractables, supporting various sterilization methods, and have passed ISO 10993 and national biocompatibility certifications [2]. - Desmopan® Rx materials are specifically designed for medical device components, including thin-walled flexible tubes, catheters, connectors, component housings, endoscopes, healthcare devices, and wearable products, with applications in surgical procedures, dialysis, drug delivery, and wound care [2]. - The series is compatible with melt-blown processes, allowing the production of medical-grade non-woven fabrics for surgical drapes, wound dressings, and surgical gowns, compliant with medical waste disposal regulations [2]. Group 2: Strategic Developments - In September of the previous year, Covestro announced the establishment of a new TPU Asia-Pacific application development center in Guangzhou, aimed at enhancing proximity to the TPU industry cluster in China and the Asia-Pacific region, particularly in consumer electronics and specialty extrusion [3]. - Covestro has initiated the construction of its largest TPU production base in Zhuhai, expected to reach an annual capacity of nearly 120,000 tons by 2033, creating a collaborative synergy among the Guangzhou application development center, Changhua R&D center, and Zhuhai production base [3].